Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.051 AUD | 0.00% |
|
-10.53% | -53.64% |
Jun. 24 | Imugene Doses First Patient of Bile Tract Cancer in Phase One Clinical Trial; Shares Decline 6% | MT |
Apr. 16 | Imugene Signs Deal to Sell Manufacturing Facility For $6 Million | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-53.64% | 249M | |
+16.59% | 44.87B | |
-10.62% | 37.8B | |
+40.49% | 37.61B | |
+29.92% | 31.32B | |
-9.78% | 27.4B | |
+12.34% | 26.32B | |
+41.53% | 14.07B | |
+31.49% | 12.5B | |
-7.40% | 11.23B |
- Stock Market
- Equities
- IMU Stock
- News Imugene Limited
- Imugene to Open Phase Two Colorectal Cancer Trial in the UK, Australia